Immunoprecise Antibodies Ltd reports results for the quarter ended April 30 - Earnings Summary

Mindwalk Holdings

29/07/2025 14:32

Immunoprecise Antibodies Ltd IPA.OQ reported a quarterly adjusted loss of 5 cents​​ per share for the quarter ended April 30, higher than the same quarter last year, when the company reported EPS of -11 cents.  The mean expectation of two analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -7 cents to -3 cents per share.

Revenue rose 8.1% to C$6.98 million from a year ago; analysts expected C$7.89 million.

Immunoprecise Antibodies Ltd's reported EPS for the quarter was a loss of 5 cents​.

The company reported a quarterly loss of C$2.16 million.

Immunoprecise Antibodies Ltd shares had risen by 90.6% this quarter and gained 390.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $4.00, about 49.5% above its last closing price of $2.02

This summary was machine generated from LSEG data July 29 at 01:31 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Apr. 30 2025
-0.05
-0.05
Met
Jan. 31 2025
-0.08
-0.01
Beat
Oct. 31 2024
-0.09
-0.09
Met
Jul. 31 2024
-0.11
-0.15
Missed